Total Payments
$821,374
2024 Payments
$128,751
Companies
44
Transactions
1,115
Medicare Patients
16,858
Medicare Billing
$5.0M
Payment Breakdown by Category
Other$646,020 (78.7%)
Travel$73,556 (9.0%)
Research$37,027 (4.5%)
Food & Beverage$32,663 (4.0%)
Consulting$31,945 (3.9%)
Education$162.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $645,760 | 252 | 78.6% |
| Travel and Lodging | $73,556 | 223 | 9.0% |
| Unspecified | $37,027 | 25 | 4.5% |
| Food and Beverage | $32,663 | 595 | 4.0% |
| Consulting Fee | $31,945 | 15 | 3.9% |
| Honoraria | $260.08 | 2 | 0.0% |
| Education | $162.99 | 3 | 0.0% |
Payments by Type
General
$784,346
1,090 transactions
Research
$37,027
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $198,553 | 290 | $0 (2024) |
| Amgen Inc. | $166,260 | 171 | $0 (2024) |
| Lilly USA, LLC | $156,392 | 131 | $0 (2024) |
| Celgene Corporation | $129,410 | 132 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $70,601 | 153 | $0 (2023) |
| UCB, Inc. | $30,709 | 53 | $0 (2024) |
| Eli Lilly and Company | $24,533 | 2 | $0 (2024) |
| Galderma Laboratories, L.P. | $12,156 | 21 | $0 (2024) |
| Janssen Biotech, Inc. | $10,265 | 35 | $0 (2022) |
| X4 Pharmaceuticals, Inc. | $6,545 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $128,751 | 131 | ABBVIE INC. ($56,084) |
| 2023 | $185,294 | 181 | Lilly USA, LLC ($76,276) |
| 2022 | $209,347 | 288 | ABBVIE INC. ($77,460) |
| 2021 | $48,015 | 105 | Amgen Inc. ($29,117) |
| 2020 | $52,480 | 94 | Amgen Inc. ($35,084) |
| 2019 | $127,298 | 180 | Celgene Corporation ($72,507) |
| 2018 | $50,105 | 87 | Celgene Corporation ($38,295) |
| 2017 | $20,084 | 49 | Celgene Corporation ($18,608) |
All Payment Transactions
1,115 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $788.22 | General |
| 12/16/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $298.96 | General |
| 12/16/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $141.87 | General |
| 12/12/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $1,302.00 | General |
| 12/12/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $124.89 | General |
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $726.18 | General |
| Category: Inflammation | ||||||
| 12/04/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $122.03 | General |
| 12/03/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $102.99 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $235.20 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $200.03 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $105.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $20.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.81 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.81 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $2,862.08 | General |
| 10/30/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $522.22 | General |
| 10/30/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $204.57 | General |
| 10/30/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $106.20 | General |
| 10/09/2024 | Galderma Laboratories, L.P. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $22,146 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension | X4 Pharmaceuticals, Inc. | $6,545 | 3 |
| A PHASE 4, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-122 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Bausch Health US, LLC | $3,000 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $2,387 | 1 |
| A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | AbbVie Inc. | $2,256 | 9 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | ABBVIE INC. | $610.44 | 8 |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | AbbVie Inc. | $56.97 | 1 |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | AbbVie Inc. | $26.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 6,713 | 14,119 | $5.0M | $1.8M |
| 2022 | 41 | 5,649 | 13,720 | $3.8M | $1.4M |
| 2021 | 36 | 2,419 | 48,706 | $2.3M | $880,969 |
| 2020 | 30 | 2,077 | 81,088 | $1.6M | $953,160 |
Total Patients
16,858
Total Services
157,633
Medicare Billing
$5.0M
Procedure Codes
163
All Medicare Procedures & Services
163 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q4180 | Revita, per square centimeter | Office | 2023 | 30 | 592 | $769,785 | $301,758 | 39.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 728 | 1,530 | $426,413 | $148,020 | 34.7% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 156 | 241 | $370,955 | $143,727 | 38.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 343 | 755 | $291,250 | $111,551 | 38.3% |
| Q4229 | Cogenex amniotic membrane, per square centimeter | Office | 2023 | 18 | 576 | $278,585 | $109,207 | 39.2% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 150 | 261 | $245,830 | $96,343 | 39.2% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 103 | 164 | $237,764 | $91,586 | 38.5% |
| 15789 | Chemical peel of deep layer of skin of face | Office | 2023 | 154 | 186 | $223,824 | $86,619 | 38.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 691 | 1,175 | $232,470 | $80,745 | 34.7% |
| 17314 | Removal and microscopic exam of growth of trunk, arms, or legs, each additional stage, 1-5 tissue blocks | Office | 2023 | 101 | 184 | $166,336 | $65,220 | 39.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 311 | 608 | $159,683 | $55,299 | 34.6% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 397 | 399 | $112,776 | $44,872 | 39.8% |
| Q4232 | Corplex, per square centimeter | Office | 2023 | 19 | 271 | $111,020 | $43,520 | 39.2% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 107 | 171 | $165,357 | $33,485 | 20.3% |
| 15793 | Chemical peel of deep layer of nonfacial skin | Office | 2023 | 107 | 123 | $132,348 | $31,602 | 23.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 315 | 381 | $89,535 | $28,394 | 31.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 238 | 238 | $85,695 | $27,062 | 31.6% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 88 | 118 | $125,644 | $26,514 | 21.1% |
| 11106 | Incision biopsy, first skin growth | Office | 2023 | 168 | 186 | $66,834 | $24,397 | 36.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 272 | 272 | $66,280 | $20,596 | 31.1% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 20 | 189 | $53,284 | $20,213 | 37.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 281 | 619 | $49,843 | $19,158 | 38.4% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 188 | 554 | $47,048 | $18,134 | 38.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 171 | 294 | $34,015 | $13,341 | 39.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 186 | 275 | $42,031 | $11,829 | 28.1% |
About Dr. Navid Ezra, M.D
Dr. Navid Ezra, M.D is a MOHS-Micrographic Surgery healthcare provider based in Thousand Oaks, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2011. The National Provider Identifier (NPI) number assigned to this provider is 1104110071.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Navid Ezra, M.D has received a total of $821,374 in payments from pharmaceutical and medical device companies, with $128,751 received in 2024. These payments were reported across 1,115 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($645,760).
As a Medicare-enrolled provider, Ezra has provided services to 16,858 Medicare beneficiaries, totaling 157,633 services with total Medicare billing of $5.0M. Data is available for 4 years (2020–2023), covering 163 distinct procedure/service records.
Ad
Practice Information
- Specialty MOHS-Micrographic Surgery
- Other Specialties Procedural Dermatology, Dermatology
- Location Thousand Oaks, CA
- Active Since 06/08/2011
- Last Updated 04/22/2024
- Taxonomy Code 207ND0101X
- Entity Type Individual
- NPI Number 1104110071
Products in Payments
- Otezla (Drug) $289,514
- TALTZ (Drug) $159,055
- SKYRIZI (Biological) $91,738
- RINVOQ (Biological) $84,987
- COSENTYX (Biological) $70,321
- Cimzia (Drug) $17,650
- OLUMIANT (Drug) $17,294
- Bimzelx (Biological) $11,350
- TREMFYA (Drug) $10,230
- XOLREMDI (Drug) $6,545
- Otezla (Biological) $6,057
- Recell (Device) $1,400
- Klisyri (Drug) $800.00
- DUPIXENT (Biological) $674.72
- ILUMYA (Biological) $472.00
- Humira (Biological) $451.77
- Sotyktu (Drug) $366.97
- OPZELURA (Drug) $325.07
- Puraply (Medical Supply) $246.78
- EUCRISA (Drug) $231.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.